ONC201 for difficult blood cancers that are back or not responding
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests ONC201, a study medicine, in adults with acute leukemia that has come back or did not respond, or high-risk myelodysplastic syndrome (MDS) that has limited treatment options. It may help shrink or control the cancer and support longer-lasting remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and have relapsed or refractory acute leukemia or high-risk MDS
- You must be well enough to do daily activities (ECOG performance status 0–2)
- If you can become pregnant, you must use reliable birth control and have a negative pregnancy test before starting; nursing is not allowed
- Your last cancer treatments must be stopped long enough before starting (at least 2 weeks for chemo-like drugs, or 5 half-lives for others)
- Your organ tests must be acceptable (kidney, liver blood tests) and you must not have significant unresolved side effects from prior treatment
- You must not have certain serious uncontrolled health problems (like uncontrolled infection or unstable heart/psychiatric issues)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a combination chemotherapy plan for certain leukemia and lymphoma types that have come back or did not respond. It may help shrink or control disease when standard treatment is no longer working.
This trial tests a combination of two oral drugs, eltanexor and venetoclax, for people with certain types of blood cancer that have come back or not responded to previous treatment. The goal is to see if this combination can help control the disease.
This Phase 2 study tests whether ONC201 given with weekly paclitaxel can control platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It may help by shrinking tumors or slowing growth in people whose cancer has progressed after platinum chemotherapy.
This Phase 1 study tests ONC206, a new targeted medicine, for diffuse midline gliomas (DMG) with a specific gene change (H3K27 altered) and for some other recurrent brain/spinal cord cancers. It is designed to find the right dose and see whether it can control or shrink tumors after initial treatment or when the cancer returns.
This Phase 1 study tests ONC201 together with atezolizumab in people with metastatic or returning endometrial cancer, especially when obesity may be driving the cancer. It aims to find a safe dose and see whether the combination can slow the cancer’s growth.
This early-phase study tests an oral medicine called ONC206 in adults with recurrent, rare brain or spinal cord tumors. The goal is to find a safe dose and look for signs the treatment can shrink or control the cancer.
Hear when a new Recurrent Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.